A Phase 1 interventional study of TAK-580 and TAK-202 in Melanoma, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-05.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1, Interventional, and Other
The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors [nivolumab, ipilimumab] with investigational drugs [TAK-580, TAK-202 (plozalizumab), vedolizumab]) in the 3 arms when administered to participants with advanced melanoma.
The drugs being tested in this study are called TAK-580, TAK-202 (plozalizumab), and vedolizumab. These investigational drugs were given along with standard of care checkpoint inhibitors ([nivolumab in Arms 1 and 2] or nivolumab + ipilimumab in Arm 3). This study looked at the safety profile of the combination treatments in each arm when administered to participants with metastatic melanoma.
The study planned to enroll approximately 156 participants. Participants were assigned to one of the 3 treatment groups:
This study consists of 3 parts. A dose-escalation safety lead-in phase, confirmatory safety phase and a cohort expansion phase. This multi-center trial will be conducted in the United States. The overall time to participate in this study is 50 weeks. Participants may make multiple visits to the clinic and 30, 60, and 90 days after last dose of study drug for follow-up assessments.
3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.
This study's enrollment of 22 is below the median of 40 across 2,649 interventional studies indexed under Melanoma.
Browse Melanoma studies →Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
First submitted after Millennium Pharmaceuticals, Inc. became part of Takeda.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Requirements for TAK-580 + nivolumab
a) BRAF V600 mutation-positive or NRAS mutation-positive disease previously untreated with RAF, MEK, or other inhibitors of the mitogen-activated protein kinase (MAPK) pathway. Participants who have progressed on these agents can still be enrolled in TAK-202 (plozalizumab) + nivolumab or vedolizumab + nivolumab + ipilimumab.
Exclusion Criteria:
Additional Exclusion Requirements for arm 1 only (nivolumab Plus TAK-580)
Additional Exclusion Requirements for arm 3 only (vedolizumab Plus nivolumab Plus ipilimumab)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAK-580 orally, once weekly along with nivolumab, intravenous, every 2 weeks.
Drug: TAK-580 · Drug: nivolumab
TAK-202 (plozalizumab) 2 milligram (mg), intravenous, once in Week 1, 3, 5, 9, and every 4 weeks thereafter with nivolumab infusion, intravenous, every 2 weeks.
Drug: TAK-202 · Drug: nivolumab
Vedolizumab intravenous, once in Week 1, 3, 5, and 13 along with nivolumab infusion, intravenous, once in Week 1, 4, 7, 10, and 13 and every 2 weeks thereafter, along with ipilimumab intravenous, once in Week 1, 4, 7, and 10.
Drug: vedolizumab · Drug: nivolumab · Drug: ipilimumab
TAK-580 tablets
Also known as: MLN2480
TAK-202 infusion
Also known as: MLN1202, plozalizumab
vedolizumab infusion
Also known as: Entyvio
nivolumab infusion
Also known as: Opdivo
ipilimumab infusion
Also known as: Yervoy
Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase
DLTs was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
Time frame: TAK-580 + Nivolumab and TAK-202 + Nivolumab: Baseline up to Week 9; Vedolizumab + Nivolumab + Ipilimumab: Baseline up to Week 7
Overall Response Rate (ORR) During the Dose-escalation Safety Lead-in Phase
ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. was the percentage of participants with complete response (CR) or partial response (PR). CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30 percent (%) decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.
Time frame: Baseline up to Week 50
Duration of Response (DOR) During the Dose-escalation Safety Lead-in Phase
DOR based on RECIST version 1.1 was the time from the date of first documented confirmed CR/PR until the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non- target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
Time frame: From date of first documented confirmed CR/PR until date of first documentation of PD or death (up to Week 50)
Progression-free Survival (PFS) During the Dose-escalation Safety Lead-in Phase
PFS was the time from first dose date to date of the first documentation of confirmed PD or death, whichever occurred first. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions.
Time frame: From first dose date to the date of the first documentation of confirmed PD or death (up to Week 50)
Overall Survival (OS) During the Dose-escalation Safety Lead-in Phase
OS was the time from date of first dose of study drug until date of death from any cause.
Time frame: From first dose of study drug until date of death from any cause (up to Week 50)
Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame: From the first dose of study drug up to 30 days after the last dose of study drug (up to Week 50)
Participants took part in the study at 10 investigative sites in the United States from 22 June 2016 to 11 May 2018.
| Milestone | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab |
|---|---|---|---|
| Started | 1 | 9 | 12 |
| Completed | 0 | 2 | 5 |
| Not completed | 1 | 7 | 7 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 6 | 6 |
DLTs was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
| DLTs | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab |
|---|---|---|---|
| Number of Dose Limiting Toxicities (DLTs) During the Dose-escalation Safety Lead-in Phase | 0 | 3 | 0 |
ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. was the percentage of participants with complete response (CR) or partial response (PR). CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to less than (\<) 10 millimeter (mm). PR: was at least a 30 percent (%) decrease in sum of diameter (SOD) of target lesions, taking as reference the baseline SOD.
No measurements were reported for this outcome.
DOR based on RECIST version 1.1 was the time from the date of first documented confirmed CR/PR until the first documentation of confirmed progressive disease (PD) or death, whichever occurred first. CR: was disappearance of all target lesions. Any pathological lymph nodes (target or non-target) had to be reduced in short axis to \<10 mm. PR: at least 30% decrease in SOD of target lesions, taking as reference the baseline SOD persistence of one or more non- target lesions and/or maintenance of tumor marker level above the normal limits. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.
No measurements were reported for this outcome.
PFS was the time from first dose date to date of the first documentation of confirmed PD or death, whichever occurred first. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions.
No measurements were reported for this outcome.
OS was the time from date of first dose of study drug until date of death from any cause.
No measurements were reported for this outcome.
| participants | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab |
|---|---|---|---|
| TEAEs | 1 | 9 | 12 |
| SAEs | 1 | 2 | 7 |
Collected over Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days (up to Week 50) after the last dose of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: TAK-580 + Nivolumab | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Arm 2: TAK-202 + Nivolumab | 0/9 (0%) | 2/9 (22.2%) | 9/9 (100%) |
| Arm 3: Vedolizumab + Ipilimumab + Nivolumab | 2/12 (16.7%) | 7/12 (58.3%) | 12/12 (100%) |
| Event | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/1 | 1/9 | 0/12 |
| Adrenal insufficiencyEndocrine disorders | 1/1 | 0/9 | 0/12 |
| Rectal haemorrhageGastrointestinal disorders | 0/1 | 1/9 | 0/12 |
| Autoimmune colitisGastrointestinal disorders | 0/1 | 0/9 | 1/12 |
| ColitisGastrointestinal disorders | 0/1 | 0/9 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 0/1 | 0/9 | 1/12 |
| HypophysitisEndocrine disorders | 0/1 | 0/9 | 1/12 |
| EosinophiliaBlood and lymphatic system disorders | 0/1 | 0/9 | 1/12 |
| LeukocytosisBlood and lymphatic system disorders | 0/1 | 0/9 | 1/12 |
| Acute coronary syndromeCardiac disorders | 0/1 | 0/9 | 1/12 |
| Event | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab |
|---|---|---|---|
| NauseaGastrointestinal disorders | 1/1 | 6/9 | 8/12 |
| FatigueGeneral disorders | 1/1 | 4/9 | 9/12 |
| HeadacheNervous system disorders | 1/1 | 3/9 | 5/12 |
| PyrexiaGeneral disorders | 1/1 | 3/9 | 5/12 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/1 | 2/9 | 2/12 |
| DehydrationMetabolism and nutrition disorders | 1/1 | 0/9 | 3/12 |
| Dry mouthGastrointestinal disorders | 1/1 | 1/9 | 2/12 |
| VomitingGastrointestinal disorders | 1/1 | 2/9 | 1/12 |
| Acute kidney injuryRenal and urinary disorders | 1/1 | 0/9 | 1/12 |
| Amylase increasedInvestigations | 1/1 | 0/9 | 1/12 |
The safety analysis set included all participants who received at least 1 dose, even if incomplete, of study treatment (TAK-580, TAK-202, or vedolizumab).
| Age, Continuous(years) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| Mean | 41 | 63.9 ± 11.54 | 55.8 ± 16.36 | 58.5 ± 14.90 |
| Sex: Female, Male(Participants) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| Female | 1 | 3 | 7 | 11 |
| Male | 0 | 6 | 5 | 11 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 1 | 9 | 9 | 19 |
| Unknown or Not Reported | 0 | 0 | 3 | 3 |
| Race (NIH/OMB)(Participants) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 |
| White | 1 | 8 | 11 | 20 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| United States | 1 | 9 | 12 | 22 |
| Height(centimeter (cm)) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| Mean | 171.00 | 168.49 ± 10.479 | 170.00 ± 10.846 | 169.40 ± 10.170 |
| Weight(kilogram (kg)) | Arm 1: TAK-580 + Nivolumab | Arm 2: TAK-202 + Nivolumab | Arm 3: Vedolizumab + Ipilimumab + Nivolumab | Total |
|---|---|---|---|---|
| Mean | 77.80 | 77.42 ± 9.248 | 88.20 ± 26.786 | 83.32 ± 20.937 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2016 to primary completion in May 2018, 22 months.
Results were first posted in Apr 2021, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tovorafenib · Plozalizumab · Vedolizumab
Millennium Pharmaceuticals, Inc. →